Switching antipsychotic therapy: What to expect and clinical strategies for improving therapeutic outcomes

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 6, 2007, Pages 10-13

  Lambert, Tim J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CHOLINERGIC ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REBOUND; REMISSION; REVIEW; SEROTONIN SYNDROME; SUPERSENSITIVITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT CARE PLANNING; PSYCHOTIC DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT FAILURE;

EID: 34347398877     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs 2005; 19:27-42
2. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200-207
3. Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003;178(suppl 9):S57-S61
4. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
5. Remington G, Chue P, Stip E, et al. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:267-272
6. Lambert TC. Switching to Risperidone [CD-ROM]. Melbourne, Australia: Janssen-Cilag Medical Education Service; 1999
7. Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing. Clin Ther 1996;18:592-607
8. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980;137:1395-1398
9. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196: 326-328
10. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135:1409-1410
11. Davis KL, Rosenberg GS. Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 1979;14:699-703
12. Zerjav-Lacombe S, Dewan V. Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine. Ann Pharmacother 2001;35:180-182
13. Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson's disease patient. Mov Disord 2002;17:1365-1367
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association; 1994
15. Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry 2005;29:145-147
16. Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 1995;19: 1323-1334